This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2001 Oct;35(4):527-30.

doi: 10.1016/s0168-8278(01)00184-2.

Amantadine for chronic hepatitis c: a magic bullet or yet another dead duck?

A Craxi, O Lo Lacono

PMID: 11682040
PMCID: PMC7172842
DOI: 10.1016/s0168-8278(01)00184-2

Review

Amantadine for chronic hepatitis c: a magic bullet or yet another dead duck?

A Craxi et al. J Hepatol. 2001 Oct.

. 2001 Oct;35(4):527-30.

doi: 10.1016/s0168-8278(01)00184-2.

Authors

A Craxi, O Lo Lacono

PMID: 11682040
PMCID: PMC7172842
DOI: 10.1016/s0168-8278(01)00184-2

No abstract available

PubMed Disclaimer

Comment on

Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre study.
Caronia S, Bassendine MF, Barry R, Mills P, Naoumov NV, Fox R, Lowes J, Hollanders D, Murray-Lyon L, Irving WL, Goldin RD, Foster GR; UK Amantadine Study Group. Caronia S, et al. J Hepatol. 2001 Oct;35(4):512-6. doi: 10.1016/s0168-8278(01)00140-4. J Hepatol. 2001. PMID: 11682036 Clinical Trial.
Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients.
Tabone M, Laudi C, Delmastro B, Biglino A, Andreoni M, Chieppa F, Bonardi R, Cariti G, Cusumano S, Brunello F, Calleri G, Manca A, Della Monica P, Sidoli L, Rizzetto M, Pera A. Tabone M, et al. J Hepatol. 2001 Oct;35(4):517-21. doi: 10.1016/s0168-8278(01)00166-0. J Hepatol. 2001. PMID: 11682037 Clinical Trial.

Similar articles

Efficacy of amantadine hydrochloride in patients with chronic hepatitis C.
Nakamura H. Nakamura H. J Gastroenterol. 2001 Nov;36(11):792-3. doi: 10.1007/s005350170025. J Gastroenterol. 2001. PMID: 11757755 No abstract available.
Amantadine: a different approach.
Torre F, Picciotto A. Torre F, et al. J Hepatol. 2002 May;36(5):705. doi: 10.1016/s0168-8278(02)00030-2. J Hepatol. 2002. PMID: 11983458 No abstract available.
Amantadine in the treatment of patients with chronic hepatitis C.
Foster GR. Foster GR. Ital J Gastroenterol Hepatol. 1998 Dec;30(6):614-5. Ital J Gastroenterol Hepatol. 1998. PMID: 10076784 No abstract available.
Role of amantadine and other adjuvant therapies in the treatment of hepatitis C.
Brillanti S. Brillanti S. Semin Liver Dis. 2004;24 Suppl 2:89-95. doi: 10.1055/s-2004-832933. Semin Liver Dis. 2004. PMID: 15346251 Review.
[Antiviral treatment of chronic hepatitis C in interferon nonresponders].
Moreno Monteagudo JA, García Buey L, Trapero Marugán M, Moreno Otero R. Moreno Monteagudo JA, et al. Gastroenterol Hepatol. 2002 May;25(5):342-6. doi: 10.1016/s0210-5705(02)79036-5. Gastroenterol Hepatol. 2002. PMID: 11985812 Review. Spanish. No abstract available.

See all similar articles

Cited by

The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.
Wanka L, Iqbal K, Schreiner PR. Wanka L, et al. Chem Rev. 2013 May 8;113(5):3516-604. doi: 10.1021/cr100264t. Epub 2013 Feb 25. Chem Rev. 2013. PMID: 23432396 Free PMC article. Review. No abstract available.
Amantadine in treatment of chronic hepatitis C virus infection?
Lim JK, Wooten D, Siegel R, Cheung RC. Lim JK, et al. J Viral Hepat. 2005 Sep;12(5):445-55. doi: 10.1111/j.1365-2893.2005.00622.x. J Viral Hepat. 2005. PMID: 16108758 Free PMC article. Review.
Treatment of chronic hepatitis C patients not responding to combination therapy with ribavirin and interferon alpha--hype or hope?
Vogel W. Vogel W. Wien Klin Wochenschr. 2004 Aug 31;116(15-16):508-10. doi: 10.1007/BF03217702. Wien Klin Wochenschr. 2004. PMID: 15471176 Free PMC article. No abstract available.
Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine.
Stauber RE, Hofer H, Hackl F, Schütze K, Datz C, Hegenbarth K, Jessner W, Steindl-Munda P, Peter F; Austrian Hepatitis Study Group. Stauber RE, et al. Wien Klin Wochenschr. 2004 Aug 31;116(15-16):530-5. doi: 10.1007/BF03217706. Wien Klin Wochenschr. 2004. PMID: 15471180 Clinical Trial.
Distribution and dynamics of adamantanes in a lipid bilayer.
Chew CF, Guy A, Biggin PC. Chew CF, et al. Biophys J. 2008 Dec 15;95(12):5627-36. doi: 10.1529/biophysj.108.139477. Epub 2008 Oct 3. Biophys J. 2008. PMID: 18835906 Free PMC article.

References

1. De Clercq E. Antiviral drugs: current state of the art. J Clin Virol. 2001;22:73–89. - PubMed
1. Wintermeyer S.M, Nahata M.C. Rimantadine: a clinical perspective. Ann Pharmacother. 1995;29:299–310. - PubMed
1. Smith J.P. Treatment of chronic hepatitis C with amantadine. Dig Dis Sci. 1997;42:1681–1687. - PubMed
1. Smith J.P. Hepatitis C treatment with amantadine-HCl in non-responders to alpha-interferon. Arq Gastroenterol. 1999;36:61–62. - PubMed
1. Tabone M, Ercole E, Zaffino C, Sallio Bruno F, Pera A, Bonino F. Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients. Ital J Gastroenterol Hepatol. 1998;30:611–613. - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources